🇺🇸 FDA

Intelligence · Patent portfolio

Alnylam Netherlands Patents

Full USPTO pharma patent portfolio for Alnylam Netherlands — grant dates, expiration, and drug cross-links.

Patents
379
Expiring ≤24m
4

Quick answer

Alnylam Netherlands has 379 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months — use filters for patent-cliff planning.

Page 4 of 8

  1. US 10465194

    Complement component iRNA compositions and methods of use thereof

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10407679

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10400238

    Polynucleotide agents targeting complement component C5 and methods of use thereof

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10400239

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10370666

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10369226

    Biodegradable lipids for the delivery of active agents

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10337010

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10273477

    Therapeutic compositions

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10266484

    Biodegradable lipids for the delivery of active agents

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10246713

    TMPRSS6 iRNA compositions and methods of use thereof

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10246708

    Dosages and methods for delivering lipid formulated nucleic acid molecules

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10238749

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10240152

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10231988

    Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10233452

    Compositions and methods for increasing erythropoietin (EPO) production

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10233448

    Modified double-stranded RNA agents

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10208307

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10195291

    Compositions and methods for the manufacture of lipid nanoparticles

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10190118

    Methods and compositions for treating insects

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10131907

    Glycoconjugates of RNA interference agents

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10125369

    PCSK9 iRNA compositions and methods of use thereof

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10119143

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10100312

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10086081

    Carbohydrate conjugated RNA agents and process for their preparation

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10077444

    Compositions and methods for inhibiting expression of the LECT2 gene

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10060921

    Methods of treating transthyretin (TTR) mediated amyloidosis

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10030244

    Serpina1 iRNA compositions and methods of use thereof

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9999673

    PEGylated lipids and their use for drug delivery

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9982263

    Conserved HBV and HCV sequences useful for gene silencing

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9970006

    Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9963700

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9957507

    Compositions and methods for inhibiting expression of mutant EGFR gene

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9944671

    Compositions and methods directed to treating liver fibrosis

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9932593

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9902955

    Method and medicament for inhibiting the expression of a given gene

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9868950

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9867882

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9850488

    Complement component C5 iRNA compositions and methods of use thereof

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9822365

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9796974

    Modified RNAi agents

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9783806

    TMPRSS6 iRNA compositions and methods of use thereof

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9771591

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9708615

    Therapeutic compositions

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9701963

    Complement component C5 iRNA compositions and methods of use thereof

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9687448

    Nucleic acid lipid particle formulations

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9682922

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9631193

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9587240

    Compositions and methods for inhibiting expression of a target gene

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alnylam Netherlands have?

379 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alnylam Netherlands patents expire?

4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.